Chinese biotechnology company Sino Biological Inc (SZ:301047) announced on Wednesday that it has launched the 2026-2027 Northern Hemisphere influenza vaccine strain antigens to accelerate vaccine development.
This follows the World Health Organization's (WHO) recommendations for the 2026-2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains.
To support global influenza vaccine research and development, Sino Biological has introduced an extensive portfolio of recombinant antigens for the 2026-2027 influenza vaccine strains, including A/Missouri/11/2025 (H1N1) HA Trimer (purity greater than 90% verified by SEC-MALS), NA, and NP proteins.
Dr. Rob Burgess, chief business officer at Sino Biological US, said: "Our mission is to provide the scientific community with the highest quality tools as rapidly as possible when infectious disease evolution threatens global health preparedness."
hVIVO secures Phase III human challenge trial contract with ILiAD Biotechnologies
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
hVIVO signs influenza human challenge trial agreement with Traws Pharma
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
GC Biopharma secures first Latin American approval for BARYCELA Inj.
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial
Delonix Bioworks gets IND clearance for DX-104 in China
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil